Latest drug discovery Stories

AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013

2013-05-03 08:25:33

REDWOOD CITY, Calif., May 3, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2013 financial results after market close on Wednesday, May 8, 2013. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific...

qPCR Assay, PDD & Benchtop Automation 2013 Market Trends

2013-05-01 08:26:34

ReportsnReports.com offers 2013 market research reports on trends in qPCR Assay, phenotypic drug discovery, benchtop automation and mass spectrometry (MS)-based screening assays. DALLAS, May 1, 2013 /PRNewswire-iReach/ -- qPCR Assay Trends 2013, Phenotypic Drug Discovery Trends 2013, Benchtop Automation Trends 2013 and Mass Spec-Based Screening Assay Trends 2013 are new reports available with ReportsnReports.com (Photo: http://photos.prnewswire.com/prnh/20130501/CG04491)...

SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board

2013-04-30 08:35:05

JUPITER, Fla., April 30, 2013 /PRNewswire/ -- SMaRT Therapeutics, Inc., a leading biotechnology company focused on the development of small-molecule drugs that target and modulate RNA, announced the appointment of Dr. John H. Abeles to its Advisory Board. Dr. Abeles has had a long and distinguished career in the biotechnology and pharmaceutical industries. He practiced medicine in London before serving as a Senior Medical Executive with Sterling Drug, Pfizer and Revlon Healthcare....

Afraxis, Inc. and Servier Announce a Collaboration on ESP Platform for Drug Discovery in Central Nervous System Disorders

2013-04-30 08:34:05

SAN DIEGO and PARIS, April 30, 2013 /PRNewswire/ -- Afraxis, Inc. ("Afraxis") and Institut de Recherches Servier ("Servier") announced a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology for the discovery of drugs to treat central nervous system (CNS) disorders. Afraxis' ESP Technology rapidly assesses complex neural networks to evaluate preclinical efficacy and safety in CNS disorders. The technology quantifies and characterizes the...

Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals

2013-04-30 08:32:39

Funding to Expand the SUREtechnology Platform(TM) GENEVA, April 30, 2013 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that it has closed an agreement with Ligand Pharmaceuticals Incorporated to sell potential milestone and royalty payments for more than 15 biologic development programs from Selexis. (Logo:...

Afraxis Appoints Carmine Stengone President and Chief Executive Officer, and Christopher Rex, Ph.D., Chief Scientific Officer

2013-04-29 08:27:44

New executive team will lead continued development and partnering of company's Enhanced Spine Platform Technology for drug discovery in CNS disorders SAN DIEGO, April 29, 2013 /PRNewswire/ -- Afraxis, Inc. today announced that it has appointed Carmine Stengone as the company's president and chief executive officer. The company has also appointed Christopher Rex, Ph.D. as chief scientific officer. In his previous role as vice president of corporate development for Afraxis...

Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda

2013-04-29 04:21:17

WELWYN GARDEN CITY, England and BOSTON, April 29, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved all milestones in its collaboration with Takeda Pharmaceutical Company. By achieving these milestones, Heptares will receive a significant payment from Takeda, under the terms of the agreement signed by the two companies in 2011. The agreement is focused on a single GPCR target nominated by...

HemoShear to Present Cardiovascular Drug Discovery Insights at Leading Scientific Conference

2013-04-25 16:29:17

CHARLOTTESVILLE, Va., April 25, 2013 /PRNewswire/ -- HemoShear LLC, a leading developer of human-relevant systems for drug discovery and development, will present cardiovascular drug discovery insights from three separate studies at the annual American Heart Association's Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) conference to be held in Lake Buena Vista, Florida on May 1-3, 2013. ATVB is the world's leading scientific conference focusing on advancement of scientific...

Lexicon To Present At The Needham Healthcare Conference

2013-04-25 08:33:12

THE WOODLANDS, Texas, April 25, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Needham Healthcare Conference on Tuesday, April 30, at 2:20 PM EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com....

Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimer's Disease Patients

2013-04-24 08:29:56

Previous Research Showed Bexarotene May Have Impact on Biomarkers in the Human Brain NEW YORK, April 24, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and BrightFocus Foundation today announced a funding collaboration that will support a Phase I human clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer's disease. Through this partnership, the organizations are working to address a gap in funding that exists for these...